Results 81 to 90 of about 19,673 (227)

Giant Pityriasis Versicolor

open access: yes
JEADV Clinical Practice, EarlyView.
Sunil Jaiswal   +4 more
wiley   +1 more source

S3 guideline diagnostics and therapy of alopecia areata – Part 1: Diagnostics and epidemiology

open access: yesJDDG: Journal der Deutschen Dermatologischen Gesellschaft, EarlyView.
Summary In the project funded by the Innovation Committee at the G‐BA, the S3 guideline for the diagnosis and treatment of AA was developed between 2023 and 2025. The interdisciplinary expert panel consisted of representatives from the German Dermatological Society, in particular from the Pediatric Dermatology Working Group, the Professional ...
Ulrike Blume‐Peytavi   +13 more
wiley   +1 more source

Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome

open access: yesActa Dermato-Venereologica, 2021
Low-dose methotrexate is widely used in mycosis fungoides and Sézary syndrome, but few studies have evaluated this treatment. The aim of this study was to evaluate the benefit/risk ratio of this regimen on skin lesions. A retrospective survey of a series
Fawaz Alenezi   +5 more
doaj   +1 more source

High Expression of Fas/CD95 on CD4+ Circulating T Cells: An Exclusion Criterion in the Diagnosis of Mycosis Fungoides?

open access: yesActa Dermato-Venereologica, 2017
The aim of this 10-year monocentric prospective study was to determine a cut-off value of Fas/CD95 expression by peripheral blood CD4+ T lymphocytes in discriminating patients with mycosis fungoides from controls with cutaneous benign lymphocytic ...
Aurélie Du-Thanh   +5 more
doaj   +1 more source

Increased Expression of Delta-like Ligand 4 in Mycosis Fungoides

open access: yesActa Dermato-Venereologica, 2020
In many malignancies, dysregulation of the Notch pathways, composed of 4 Notch receptors (Notch1–4) and 5 Notch ligands (Jagged1–2, Delta-like ligand-1, 3–4), is associated with their development.
Hikari Boki   +8 more
doaj   +1 more source

Folliculotropic mycosis fungoides

open access: yesDermatology Online Journal, 2007
A 72-year-old man presented with a 4-year history of asymptomatic erythematous plaques on his face, neck, and scalp. He had no systemic symptoms or lymphadenopathy. Histopathologic examination of a skin biopsy specimen showed a dense, diffuse infiltrate of lymphocytes and plasma cells, with epidermotropism and folliculotropism.
Hunzeker, Christopher M   +2 more
openaire   +4 more sources

Alopecic Patches on the Extremities of a Young Man

open access: yes
JEADV Clinical Practice, EarlyView.
Hamad El Hajj   +3 more
wiley   +1 more source

Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma [PDF]

open access: yes, 2016
Cutaneous T-cell lymphoma (CTCL) is characterized by proliferation of malignant T cells in a chronic inflammatory environment. With disease progression, bacteria colonize the compromised skin barrier and half of CTCL patients die of infection rather than
Abrahmsén   +94 more
core   +2 more sources

scRNA‐Seq reveals anti‐lymphoma immune responses in mogamulizumab‐associated skin eruptions

open access: yesJournal of the European Academy of Dermatology and Venereology, EarlyView.
CCR4 was expressed in malignant clones and regulatory T cells in untreated CTCL, that were decreased in MAR. Malignant clones in MAR showed a silenced phenotype with decreases in central memory markers SELL and CCR7, and GTP‐binding member GIMAP7 and upregulation of MMP2 inhibitor TIMP2 and tumour suppressor gene RUNX3.
Shannon Meledathu   +13 more
wiley   +1 more source

Molecular cytogenetic characterization of breakpoints in 19 patients with hematologic malignancies and 12p unbalanced translocations [PDF]

open access: yes, 2003
Structural rearrangements of the short arm of chromosome 12 are frequent cytogenetic findings in various hematologic malignancies. The ETV6 gene is the most common target for rearrangements in 12p13.
Calasanz-Abinzano, M.J. (Maria Jose)   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy